DEPLOY

Buying guide

Stelo vs Withings ScanWatch in 2026

Comparing 2 humanoid robots across availability, pricing, capabilities, and verified deployments. Current as of 2026.

Key differences

On DEPLOY's record, Stelo has more verified real-world deployments (2 versus 1) than Withings ScanWatch as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source.

  • Stelo has the lower recorded price.
  • Stelo has more verified real-world deployments (2 vs 1).
Attribute
Trying a Dexcom G7 sample for my Diabadass #diabetes #t1d #dexcom #dexcomg7 #typeonediabetes
SteloView full model page →
Glucose monitoring, glaucoma visual field virtual reality, and the new Withings BodyScan 2
Withings ScanWatchView full model page →
ManufacturerDexcomWithings
Form factorbiometricbiometric
Maturitycommercialcommercial
Autonomy——
Availabilityshipping-nowshippingshipping-nowshipping
Price$89-$99 (actual sale price)$349-$600 (actual sale price)
Capability claims——
Brain——
Verified deployments2Dexcom, Dexcom1Withings
Privacy practices4biometric-storage, training-data-use, third-party-sharing, data-deletion-control4biometric-storage, data-sale, data-deletion-control, data-retention
Sources on file1210

Track this matchup

Get told the moment Stelo or Withings ScanWatch changes. Verified changes only, the second they are real. No press-release noise.

Stelo

Verified changes only. No press-release noise.

Withings ScanWatch

Verified changes only. No press-release noise.

Editorial summaries

Stelo

Dexcom's Stelo is the first-ever FDA-cleared over-the-counter (no-prescription) glucose biosensor (De Novo, March 5, 2024; US launch August 26, 2024): a 15-day continuous glucose monitor for adults 18+ not on insulin (type 2 not on insulin, plus non-diabetic users tracking how diet and exercise affect glucose). It is the generative-AI end of the glucose cell: Weekly Insights run on Google Cloud's Vertex AI and Gemini, with AI photo meal-logging and personalized daily recommendations, the AI substance that carries it across the biometric boundary.

Pricing is about $89 for a 2-week sensor on a biweekly subscription model (around $99/month). From DexCom (NASDAQ: DXCM), Stelo is the OTC product line, separate from the prescription G7. Cap-flag: the cleared indication is an OTC CGM for adults 18+ not on insulin; it is explicitly NOT cleared for problematic hypoglycemia and has no low-glucose alerts, so it should not be read as a diabetes-management device.

Withings ScanWatch

The Withings ScanWatch (the ScanWatch 2 at about $349 and the ScanWatch Nova, including the Nova Brilliant at about $600, November 2024; from Withings, founded 2008 in France and independent since buying itself back from Nokia in 2018) is the hybrid-analog entry of the biometric cohort: a conventional analog watch dial paired with medical sensors (optical PPG, electrical ECG, SpO2, and TempTech24/7 continuous temperature) and about 30-day battery. Its cleared features include ECG (for AFib, sinus rhythm, and high heart rate, cleared 2021, with an OTC ECG clearance in 2025), SpO2 with breathing-disturbance detection, and temperature trends, with an optional Withings+ subscription (~$9.95/month).

It carries substantial peer-reviewed cardiologist validation for the size of the company. Cap-flag: as a French maker it is cleared in both the EU and the US, with different specific indications by region.

Common questions

How do Stelo and Withings ScanWatch differ?
On DEPLOY's record, Stelo has more verified real-world deployments (2 versus 1) than Withings ScanWatch as of 2026; DEPLOY counts a deployment only when confirmed at a named site with a primary source. Stelo has the lower recorded price. Stelo has more verified real-world deployments (2 vs 1).
What is the difference between Stelo and Withings ScanWatch?
Stelo and Withings ScanWatch are both biometric robots on the DEPLOY registry. They differ in maker, maturity, price, verified deployments, and how much of their autonomy is independently verified. See the table above for the full head-to-head; each figure is sourced.
Which is cheaper, Stelo or Withings ScanWatch?
Stelo has the lower recorded price on the DEPLOY registry than Withings ScanWatch. Prices are sourced; see each record for whether the figure is a manufacturer target, an estimate, or an actual sale price.
Which has more verified deployments, Stelo or Withings ScanWatch?
Stelo has more verified deployments (2) on the DEPLOY registry than Withings ScanWatch (1). DEPLOY counts a deployment only when confirmed at a named site with a primary source.

Recent coverage

Related comparisons

Keep researching

Keep reading

AI wearable prices: every verified figureAnswer The verified list.All biometric wearablesRegistry Every verified record in the category.SteloModel The full model page.Withings ScanWatchModel The full model page.DexcomRecord The maker's verified record.WithingsRecord The maker's verified record.

Ask the registry

For AI assistants

Use DEPLOY in Claude, Cursor, and other AI assistants

Connect any MCP-aware assistant to the live registry. Ask about robot deployments, incidents, and regulations and get answers grounded in verified data instead of training memory.

Install instructionsDownload for Claude Desktop

Machine-readable: this page as markdown.

← Back to all consumer robots